[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368160-105":59,"doc-detail-368160-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","loss-of-kmt2c-or-kmt2d-primes-urothelium-for-tumorigenesis-and-redistributes-kmt2a-menin-to-bivalent-promoters","Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A - menin to bivalent promoters","","KMT2C and KMT2D are recurrently mutated epigenetic regulators in urothelial carcinoma and in histologically normal urothelium. Using genetically engineered mouse models, Kmt2c/d knockout restricted to the urothelium impaired differentiation, enhanced responses to growth and inflammatory stimuli, and increased sensitivity to oncogenic transformation. Loss reduced H3K4me1, H3K27ac and nascent transcription at lineage-active enhancers and CpG-poor promoters. KMT2A - menin redistributed to CpG-high and bivalent promoters, derepressing immediate early genes, while elevating EGFR signaling and creating vulnerability to EGFR inhibitors.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/loss-of-kmt2c-or-kmt2d-primes-urothelium-for-tumorigenesis-and-redistributes-kmt2a-menin-to-bivalent-promoters/368160/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/loss-of-kmt2c-or-kmt2d-primes-urothelium-for-tumorigenesis-and-redistributes-kmt2a-menin-to-bivalent-promoters/368160.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main finding about Kmt2c/d loss in the urothelium?","Question",{"text":112,"@type":113},"Kmt2c/d knockout primes histologically normal urothelium for oncogenic transformation by impairing differentiation and sensitizing cells to growth, inflammatory stimuli, and carcinogenic/oncogenic drivers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does Kmt2c/d loss affect enhancer and promoter chromatin features?",{"text":117,"@type":113},"Kmt2c/d knockout diminishes H3K4me1, H3K27ac, and nascent RNA transcription at lineage-regulating enhancers and CpG-poor promoters, leading to impaired differentiation.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is KMT2A - menin redistribution important in this study?",{"text":121,"@type":113},"KMT2A - menin relocates from KMT2D-bound enhancers to CpG-high and bivalent promoters, which derepresses signal-induced immediate early genes and supports tumorigenic priming.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368160,1790886517,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","nature genetics  \nArticle [https://doi.org/10.1038/s41588-024-02015-y](https://doi.org/10.1038/s41588-024-02015-y)  \nLoss ofKmt2corKmt2d primesurothelium for tumorigenesis andredistributes KMT2A–meninto bivalent promoters  \nReceived: 20 June 2023  \nAccepted: 23 October 2024  \n\n| Published online: 13 January 2025 |\n| --- |\n|  Check for updates |\n\nNaitao Wang1,10, Mohini R. Pachai1,10, Dan Li  1,10, Cindy J. Lee1, Sarah Warda  1, MakhzunaN. Khudoynazarova1, Woo Hyun Cho  1, Guojia Xie2, Sagar R. Shah3,4, Li Yao  4,5, Cheng Qian1, Elissa W. P. Wong1, Juan Yan1, Fanny V. Tomas1, Wenhuo Hu1, Fengshen Kuo  6, Sizhi P. Gao1, Jiaqian Luo  1, Alison E. Smith  1, Ming Han7, Dong Gao  7, Kai Ge2, Haiyuan Yu  4,5, SaratChandarlapaty  1,8,9, Gopakumar V. Iyer  8,9, Jonathan E. Rosenberg8,9, David B. Solit  1,8,9,  \nHikmatA. Al-Ahmadie  1,6, Ping Chi  1,8,9  & Yu Chen  1,8,9   \nMembers of the KMT2C/D–KDM6A complex are recurrently mutated inurothelial carcinoma and in histologically normal urothelium. Here, using genetically engineered mouse models, we demonstrate that Kmt2c/d knockout in the urothelium led to impaired differentiation, augmented responses to growth and inflammatory stimuli and sensitization tooncogenic transformation by carcinogen and oncogenes. Mechanistically, KMT2D localized to active enhancers and CpG-poor promoters that preferentially regulate the urothelial lineage program and Kmt2c/d knockout led to diminished H3K4me1, H3K27ac and nascent RNA transcription at these sites, which leads to impaired differentiation. Kmt2c/d knockout further led to KMT2A–menin redistribution from KMT2D localized enhancers to CpG-high and bivalent promoters, resulting inderepression of signal-induced immediate early genes. Therapeutically, Kmt2c/d knockout upregulated epidermal growth factor receptor signaling and conferred vulnerability to epidermal growth factor receptor inhibitors. Together, our data posit that functional loss ofKmt2c/d licensesa molecular ‘field effect’priming histologically normal urothelium foroncogenic transformation and presents therapeutic vulnerabilities.  \nThe urothelium lines the renal pelvis, ureters, bladder and proximal urethra. Urothelial carcinoma is classified as non-muscle invasive, which can be treated with local excisions and intravesical therapy, or muscle-invasive bladder cancer (MIBC), which requires cystectomy and chemotherapy. Urothelial carcinoma is highly relapsing, often at distinct sites1, and sequencing studies have shown that spatiallyseparated urothelial carcinoma of bladder and renal pelvis are frequently clonally related2. Thus, urothelial carcinoma has been hypothesized  \nto arise from a field of precancerous, molecularly perturbed but histologically normal urothelium3,4.  \nBoth non-muscle-invasive urothelial carcinoma and MIBC frequently harbor mutations in epigenetic modifiers (for example, loss-of-function mutations in KDM6A, KMT2C, KMT2D, STAG2 and ARID1A)5,6. Two recent studies of histologically normal urothelium identified frequent loss-of-function mutations inKDM6A, KMT2C, KMT2D, STAG2 andARID1A, whereas mutationsinFGFR3, KRAS, PIK3CA,  \nA full list of affiliations appears at the end of the paper. [e-mail:](e-mail: chip@mskcc.org)[ chip@mskcc.org](e-mail: chip@mskcc.org); [cheny1@mskcc.org](cheny1@mskcc.org)  \nNature Genetics | Volume 57 | January 2025 | 165–179 165  \nTP53 andRB1 were uncommon7,8, suggesting that mutations of epigenetic modifiers are early tumorigenic events that may underlie field cancerization. Thelysine methyltransferases KMT2C or KMT2D together with the lysine demethylase KDM6A are core components of the KMT2C/D–KDM6A complex that mediate monomethylation of histone H3K4 at enhancers9–12. Prior studies have shown that loss ofKDM6A leads to disruption of urothelial differentiation13,14. Mouse bladder cancers generated by N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN), a carcinogen found in tobacco15, also harbor prevalent mutationsin the KMT2C/D–KDM6A complexes16. ","cbCaihM5TSbzk4zI","https://ap.wps.com/l/cbCaihM5TSbzk4zI","pdf",22828436,43,"English","# Background\n## Urothelial cancer and the field effect hypothesis\n## Epigenetic modifier mutations in urothelial cancer\n# Methods\n## Genetically engineered mouse model and conditional knockout\n## Assessments of deletion and transcriptional/epigenetic changes\n# Results\n## Kmt2c/d loss is insufficient to induce urothelial carcinoma","[{\"question\":\"What is the main finding about Kmt2c/d loss in the urothelium?\",\"answer\":\"Kmt2c/d knockout primes histologically normal urothelium for oncogenic transformation by impairing differentiation and sensitizing cells to growth, inflammatory stimuli, and carcinogenic/oncogenic drivers.\"},{\"question\":\"How does Kmt2c/d loss affect enhancer and promoter chromatin features?\",\"answer\":\"Kmt2c/d knockout diminishes H3K4me1, H3K27ac, and nascent RNA transcription at lineage-regulating enhancers and CpG-poor promoters, leading to impaired differentiation.\"},{\"question\":\"Why is KMT2A - menin redistribution important in this study?\",\"answer\":\"KMT2A - menin relocates from KMT2D-bound enhancers to CpG-high and bivalent promoters, which derepresses signal-induced immediate early genes and supports tumorigenic priming.\"}]","Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A - menin to bivalent promoters | PDF",1790175347,108,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a8136eb828c57bbb42961f579404cd6.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53bb592da937a4c5f549d943863be08f.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3ad6df6fca09b1423a14d20d46414e9b.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf2420046faf23a93ab7363c1b5415aa.webp",980,1301,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34b44f1a72aeb9e25bffc1ac97c25cc4.webp",979,1300]